Business
inSignals Neurotech receives EUR100,000 investment
inSignals Neurotech receives EUR100,000 investment.
About this update from Frontier Ip Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8470R\n Frontier IP Group plc\n 11 March 2021\n \n \n \n \n REACH - non-regulatory announcement \n \n \n AIM: FIPP\n \n \n 11 March 2021\n \n \n \n \n \n Frontier IP Group Plc\n \n \n (\"Frontier IP\" or the \"Group\")\n \n \n \n \n \n \n \n \n \n \n \n \n Portfolio news - inSignals Neurotech receives \n \n \n €\n \n \n 100,000 investment from \n \n \n \n Portugal Ventures \n \n \n \n \n \n \n \n Frontier IP, a specialist in commercialising intellectual property (\"IP\"), today announces that portfolio company inSignals Neurotech (\"inSignals\" or \"the Company\") has received a €100,000 investment from leading Portuguese venture capital firm Portugal Ventures through its initiative Call INNOV-ID. \n \n \n \n \n The funding will be used by inSignals to accelerate the validation and development of its patented technology to aid deep brain stimulation surgery on patients suffering Parkinson's disease. It will also \n support validation of other applications in neurology\n .\n \n \n \n \n \n In particular, it will allow the Company to expand preliminary clinical trials, strengthen its intellectual property position and grow its team. The Company was selected as a 'one to watch' in the Nature Spinoff Prize 2020 and has already received interest from potential industry partners. It is entering collaboration agreements to extend multi-centre clinical studies in Portugal, the Netherlands, Germany and Spain. \n \n \n \n \n \n Frontier IP holds a 33 per cent equity stake in inSignals. The Company, a spin out from the Portuguese Institute for Systems and Computer Engineering, Technology and Science (\"INESC TEC\") with the support of São João University Hospital, part of the University of Porto, is developing wireless wearable devices to precisely measure wrist rigidity to help surgeons place brain implants more accurately to achieve the best clinical results. \n \n \n \n \n \n Call INNOV-ID is focused on investing in science and technology projects or companies in pre-seed, seed or early stage where the technology is still at a prototype, proof of concept or product market fit validation stage. It was launched in response to a request from the Portuguese government to support technology companies through the COVID-19 pandemic. It is mana...